Form 4: Enliven Therapeutics CFO Benjamin Hohl Executes Option Exercise and Stock Sale Under 10b5-1 Plan

Sentiment:

SEC Form 4 Filing


Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options and sold shares according to a pre-arranged Rule 10b5-1 trading plan.

Summary

  • On May 3, 2024, Benjamin Hohl, the CFO of Enliven Therapeutics, exercised options to purchase 1,000 shares of common stock at a price of $2.48 per share.
  • Simultaneously, Hohl sold 1,000 shares of common stock at a price of $22.50 per share.
  • These transactions were executed under a pre-existing Rule 10b5-1 trading plan adopted on June 26, 2023.
  • Following the reported transactions, Hohl directly owns 221,120 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company executives. The use of a 10b5-1 trading plan is a common practice to avoid accusations of insider trading.

Stakeholder Impact

  • The transactions may have a minor impact on shareholders due to the sale of shares by a company executive, but the existence of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

DateDescription
June 26, 2023Date the Reporting Person adopted a Rule 10b5-1 trading plan
August 2, 2022Date of initial vesting of the option for one-fourth of the shares
May 3, 2024Date of the stock option exercise and sale of shares
May 7, 2024Date of the signature on the Form 4 filing
August 2, 2031Expiration date of the stock option

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.